IMMUNOSTIMULATORY ADJUVANTS MARKET ANALYSIS

Market Challenges And Opportunities

Immunostimulatory Adjuvants Market – Dynamics

Increasing government initiatives to prevent epidemic due to various chronic diseases and increasing national immunization programs around the globe to promote health awareness regarding vaccination among the population has boosted the growth of the immunostimulatory adjuvants market size. For instance, the Global Vaccination Action Plan (GVAP) was endorsed by the heath ministers of 194 member’s states of the world health assembly in 2012. The aim of the Global Vaccination Action plan was to introduce new improved vaccines, advance research work for next generation vaccines, and to strengthen routine immunization. GVAP urges countries to strengthen governance of national immunization programs and to keep up-to-date monitoring of data. Moreover, private organizations intervention at the global scale for the better vaccines research and development has propelled the market growth. For instance, The Bill and Melinda Gates Foundation in 2010, pledged US$ 10 billion to support the vaccine research and the development and delivery of vaccines to the underdeveloped countries. Furthermore, increasing prevalence of the chronic disease such as rubella and measles around the globe has significantly bolstered the immunostimulatory adjuvants market growth. For instance, according to the Centers for Disease Control and Prevention (CDC) facts more than 100,000 children born every year with congenital rubella syndrome mainly in the Western Pacific region, South East Asia, and Africa region. Furthermore, the World Health Organization (WHO) estimated around 145,700 deaths globally from measles in 2013. These incidences have led government and national organization to invest more into adjuvant vaccines market significantly. However, strict regulatory requirements and huge investment required for developing a new adjuvant are expected to hinder the growth of global immunostimulatory market.